PW Medtech Group Ltd

PW Medtech Group Ltd maintains a strong liquidity position, with a current ratio of 10.89, indicating a high ability to meet short-term obligations. The company's cash and equivalents amount to 1.8 billion CNY, significantly exceeding its total liabilities of 1.28 billion CNY. The debt-to-equity ratio is 0.01, suggesting a conservative capital structure with minimal reliance on debt financing. In terms of profitability, the company's return on equity (ROE) is 2.39%, and its return on assets (ROA) is 1.8%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming relative to its peers in terms of generating returns from equity and assets. The net income of 94.374 million CNY is derived from a gross profit of 407.459 million CNY, with an operating income of 122.3 million CNY. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. Geographically, the company's exposure is not disclosed in the available data, but the lack of segmental or geographic diversification may pose a concentration risk. Looking ahead, the company's revenue is expected to grow, though the exact magnitude is not specified in the available data. The company's historical revenue of 823.505 million CNY provides a baseline for assessing future performance. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative capital structure and strong cash reserves reduce the likelihood of near-term dilution. Recent events, including analyst estimates and filings, suggest that the company's performance is in line with expectations. The last actual EPS was 0.05 CNY, and the last actual revenue was 362.183 million CNY. These figures provide a snapshot of the company's recent financial performance and may influence investor sentiment.